Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
Portfolio Pulse from
Bristol Myers Squibb has received approval from the European Commission to expand the use of its CAR T Cell Therapy, Breyanzi, for treating relapsed or refractory follicular lymphoma.
March 14, 2025 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's CAR T Cell Therapy, Breyanzi, has been approved by the European Commission for expanded use in treating relapsed or refractory follicular lymphoma.
The approval from the European Commission is a significant regulatory milestone for Bristol Myers Squibb, potentially increasing the market for Breyanzi in Europe. This could lead to increased revenues and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100